MedWatch

Orphazyme files for delisting in US

A voluntary delisting of biotech company Orphazyme is expected to come into effect on March 31.

Photo: Orphazyme / PR

Embattled biotech company Orphazyme has filed for a voluntary delisting of its American Depositary Shares (ADS) from Nasdaq Global, a company press release reports on Monday evening.

”The delisting is expected to become effective on March 31, 2022,” the statement reads.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs